Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18778601 | 0.86 | CES2 (0.34) | SMN1; SMN2POLBKMT2ARAB9A | |
| SCHEMBL24539382 | 0.81 | TAAR1 (0.37) | SMN1; SMN2GAATAAR1POLBHPGD | |
| SCHEMBL321378 | 0.78 | GAA (0.42) | SMN1; SMN2GAATAAR1HPGDKMT2A | |
| SCHEMBL29469267 | 0.78 | GAA (0.42) | SMN1; SMN2GAATAAR1HPGDKMT2A | |
| SCHEMBL25960385 | 0.78 | ORAI1 (0.46) | SMN1; SMN2GAAHPGDKMT2ARAB9A | |
| SCHEMBL9945890 | 0.74 | TAAR1 (0.41) | SMN1; SMN2GAATAAR1KMT2ABACE1 | |
| SCHEMBL29922740 | 0.73 | HTR1A (0.39) | SMN1; SMN2GAATAAR1POLBKMT2A | |
| SCHEMBL24539843 | 0.71 | TAAR1 (0.42) | GAATAAR1KMT2ABACE1KDM4E | |
| SCHEMBL16854674 | 0.71 | TSHR (0.41) | KMT2ALMNA | |
| SCHEMBL16104430 | 0.70 | ENPP2 (0.45) | SMN1; SMN2HPGDKMT2ATP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | SMN1; SMN2 3268/4885GAA 810/4885TAAR1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.